PROGRAM BOUNTY

NEW DIGIPHARM-BLOCKCHAIN-BASED INNOVATIONS FOR THE

best wishes for you all this time I will discuss about new innovations based blockchain for the future that is DIGIFPHARM for more details and details please read my article below hopefully you are interested in what I write this

Real-world evidence (RWE) plays an increasingly influential role in informing decision-making within the healthcare industry and is essential to providing information on value-based health care. However, RWE output delays, data access fees and data collection methods currently eliminate many benefits of using this rich data source. The lack of an accessible and comprehensive RWE currently prevents health care stakeholders to evaluate the real time performance and value that therapy provides in real life clinical practice as part of a value-based healthcare delivery system.

| DIGIPHARM VISION

Digipharms' vision is to be a pioneer in delivering value-based care, innovative generation of generations and patient empowerment in the healthcare industry using revolutionary blockchain technology.

PROBLEM AND SOLUTIONS

PROBLEM

Barriers to innovative pricing and 'pay performance'

Health systems are often asked to make difficult decisions about whether to replace costly pharmacologic therapies and provide access to patients while considering their limited resources. This innovative pricing approach has the ability to overcome the challenges faced by the health care system when assessing new drug funding, to enable the implementation of a 'flexible' pricing scheme to assess treatment rates in relation to the benefits it provides. Unfortunately, health systems around the world do not have the relevant infrastructure to track and implement innovative pricing models such as value-based pricing agreements, and are therefore reluctant to implement such innovative policies. This leads to new pharmacological therapies being rejected by the most needy patients, the opportunity to reduce the economic burden and long-term illnesses in the health system, and barrier reimbursement for producers.

SOLUTION

Reimburse

The Reimburse platform utilizes the benefits of automated 'smart contracting' and blockchain technology; facilitate the adoption of a truly dynamic innovative pricing solution between healthcare and producer systems, in a safe and secure manner with minimal administrative burden. The use of the Reimbursement platform will accelerate the integration, coordination and delivery of a patient-centered health care system with a focus on improving patient outcomes while accelerating payer-payer mechanisms between payers and producers using mutually sustainable agreements.

Insights

Platform Insights will extract anonymous patient-level data from Reimburse platforms and health information systems to the world's RWE live database. Insights will provide a symbiotic solution with Reimburse to complement the progressive transformation toward a value-based health delivery system. The development of a 'live' repository will enable knowledge integration back into the delivery system in real time to facilitate decision-making, drug development and health-related research. Patients will be given an incentive to donate their health information to the Insight platform and will gain access to valuable health information that is currently unreachable.

Market potential

The Reimburse platform has enormous potential for absorption, with the possibility of being the ultimate platform for innovative pricing solutions for any approved regulatory therapy. There is currently no comparative platform available that can provide scalable dynamic pricing solutions to facilitate funding solutions between producer and payer.

As pharmaceutical innovation develops further, it is expected hundreds of new agents will be approved within the next 5 years. There are more than 7,000 drugs in clinical development worldwide, more than ever before (PhRMA 2017); with more than 450 new clinical trials starting in 2017 alone (Reuters 2017). Experts estimate that of the 7000 drugs under development there are about 70% who have the potential to be first in the class. Furthermore, individual drugs are being investigated in different areas of the disease to find populations that would benefit from treatment. In some areas of the disease, combining several innovative drugs to support the best outcomes for patients is being actively investigated (eg for treating cancer). With high-level innovation ready to provide unparalleled benefits to patients, health care systems and manufacturers need to work together to agree on innovative pricing solutions accordingly.

Cancer drugs have been the most widely studied in recent years and are driving the growth of pharmaceutical drug networks. This poses considerable challenges because these drugs often label high prices that explain the benefits they get. The cost of patented cancer drugs in the US alone has increased 5-10 times since the turn of the century, with median drug therapy costs around $ 100,000 per year with patients generally responsible for 20-30% as co-payment Kantarijan et al 2014). High prices for innovative therapies that may or may not work may result in patients refusing treatment or choosing a less than optimal maintenance plan due to financial difficulties they may face (Zafar et al 2013). In the United States, UnitedHealth, Aetna and Anthem's major payers almost reach their current target of 50% of total annual health care spending through value-based care and simple 'pay for performance' deals (Forbes 2017). Aetna is trying to lead the industry with a 75% value-based spending model by 2020, as they hope to build on their current initiatives to improve the quality of services and lower costs simultaneously (Forbes 2017; Bach & Pearson 2015).

Therefore, the potential of the Reimburse platform is enormous as it will be able to support smart contracts for new and existing treatments as health systems around the world continue to drive the transformation into value-based care.

Blockchain technology & smart contract applications

Blockchain is a distributed database technology, best known as the backbone of digital currency platforms such as Bitcoin and Ethereum networks. A smart contract is a code of its own executing code that digitally facilitates, verifies, or implements the terms of a predetermined agreement. This contract allows transactions to be conducted between parties anonymously without the need for enforcement or external action. All transactions based on smart contracts are published to the blockchains ledger and provide transparency and conservation. In the DPH health economy, the following characteristics of blockchain technology are used:

• Smart contract
• Private Channels
• Digital Identity Services
• Smart contract

Smart contracts will be used to facilitate innovative pricing agreements and exchange of data between health stakeholders.

Private channels on a fully independent platform

Due to the nature of the secret price agreement between stakeholders and sensitive patient data, Digipharm's digital blocked secure channel will be used to transmit sensitive information and to comply with all data compliance, regulatory and data protection laws.

Digital identity service
The digital identity service provided by blockchain will be used to create profiles for registered patients and other stakeholders while maintaining anonymity within each platform.

Digipharm Token

Use of DPH token

Digipharm (DPH) tokens will be used to pay license fees / access on the Digipharm platform. Access fees will always be determined and fixed in USD value and the number of tokens required will depend on the type of access (producer, patient, payer or provider) combined with the necessary interaction form. The quantity of tokens required for such interactions may change, relative to the market value of the DPH.

Reimburse

Reimburse

The payer / producer will be required to use the DPH token to initiate or implement a smart contract in the Reimbursement module and enroll each patient on this smart contract, ie the DPH token will be used to facilitate the process of annexing the patient to an innovative pricing and replacement agreement.

Insights

Insights

DPH will be used as a utility token to power any interaction with the healthcare Insight database by which the DPH token will be used for permissions or specific data requests from the Insight platform.

DPH token characteristics

DPH Supply: 100,000,000 Fixed (ERC-20)

Ticker code: DPH

Decimal Places: 18

Token Price 1.00 USD

Sales information of DPH token

Pre - Sale: 15,000,000 DPH

Base Price: 1.00 USD

Pre - Sale Length: 4 Weeks

Pre - Sale Discount: 35%

Main Sale: 50,000,000 DPH

Week 1: 25% Frozen 25 million tokens

Week 2: 15% Frozen 15 million tokens

Week 3: 10% Frozen 10 million tokens

Week 4: 1.00 USD

Sales information of DPH token

Use of funds and distribution of tokens

| Commitment to charity

0.5% of ICO proceeds will be allocated to the Digipharm charity foundation (to be established) with the aim of developing sustainable health-related services in third world countries. Digipharm will then make 2.5% of the net profit per year on charitable foundations. If the foundation can not be established due to regulatory or legal reasons, Digipharm intends to allocate the above funds to a third party foundation with the same purpose.

OUR TEAM

Our Advisors

for more information visit here:

twitter: https://twitter.com/DigipharmTeam

facebook: https://www.facebook.com/digipharmteam/

website: https://www.digipharm.ch/

whitepaper: https://digipharm.ch/docs/DigipharmWP.pdf

thread bounty: https://bitcointalk.org/index.php?topic=3083623.0

Author           : Raditya119

Address       0xb05e97cCA79F2562D2874c2E4E88EDD73C5eeD33

Profill Link     : https://bitcointalk.org/index.php?action=profile;u=1840762